AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01150461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: Losartan 50 mg b.i.d
Study NCT01150461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo b.i.d.
Study NCT03105063 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound scan of the hip
Description: validation of Ultrasound test as a tool for diagosing AIIS morphology
Study NCT02968238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: 10 weekly sessions of cognitive-behavioral therapy
Study NCT02968238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: 10 weeks of biweekly yoga sessions (N = 20)
Study NCT00447590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAP-BAND System
Description: Restriction of food intake
Study NCT01592396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg
Description: Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 mg, subcutaneously on Day 1.
Study NCT04324190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided online support program
Description: Guided online support program consisting of several modules; Module General information ... is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)
Study NCT04324190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided online support program
Description: Guided online support program consisting of several modules; Module General information ... is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)
Study NCT04324190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WHO recommendations (waiting condition)
Description: During the waiting period, a german translation of the WHO recommendations Coping with stress during the 2019-nCoV outbreak is provided
Study NCT00491621 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery or biopsy of the kidney tumor
Description: surgery or biopsy of the kidney tumor
Study NCT03080142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Patients will receive an injection of 30ml of volume to each abdominal side with a total of 60 ml for bilateral TAP blocks.
Study NCT03080142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patients will receive 30ml of ropivicaine. Peripheral nerve catheters will be placed approximately 3-5cm into the TAP space and secured to the skin with tegaderm tape. Infusions will be ordered with CADD pumps and will be initiated at a rate of 8ml/hr of 0.2% ropivicaine on the inpatient floor.
Study NCT03430050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Progesterone capsule
Study NCT03430050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule. Manufactured to mimic progesterone 200mg capsule.
Study NCT02772718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOMA 358 single dose level A
Description: XOMA 358 single dose level A administered by intravenous infusion
Study NCT02772718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOMA 358 single dose level B
Description: XOMA 358 single dose level B administered by an intravenous infusion
Study NCT02772718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOMA 358 single dose level C
Description: XOMA 358 single dose level C administered by an intravenous infusion
Study NCT02772718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOMA 358 multiple dose level 1
Description: XOMA 358 multiple dose level 1 administered by an intravenous infusion
Study NCT04239456 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RehaCom (software)
Description: RehaCom software has gamified, interactive modules that will help participants practice the application of various memory strategies at custom, increasingly more difficult levels. Instructor will also use the software to teach and demonstrate the use of memory strategies with the domains targeted (i.e., list learning, remembering written/verbal information, and memory for names/faces).
Study NCT01841697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks
Study NCT01841697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100 mg oral tablet once a day for 24 weeks
Study NCT01841697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to omarigliptin
Description: Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks
Study NCT01841697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Sitagliptin
Description: Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks
Study NCT01841697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Metformin
Description: Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day
Study NCT01841697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open-label Metformin
Description: Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day
Study NCT01841697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Glimepiride
Description: Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
Study NCT01841697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open-label Glimepiride
Description: Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
Study NCT00678483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimonabant (SR141716)
Description: once daily
Study NCT00719043 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/turkey H5N1 vaccine
Description: Administered as an intramuscular (IM) injection
Study NCT03729791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
Study NCT03729791 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
Study NCT00791700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc will be administered twice daily either as a liquid or tablet formulation, depending on the age of the subject. The dosage administered will be dependent upon the subject's body surface area as well as the background therapy.
Study NCT01874418 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biomarker
Description: Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
Study NCT02074800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328 (Sp2/0-derived)
Description: Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
Study NCT00719043 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: A/turkey H5N1 vaccine
Description: Administered as an intramuscular (IM) injection
Study NCT00719043 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
Description: Administered as an intramuscular (IM) injection
Study NCT00719043 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an intramuscular (IM) injection
Study NCT00719043 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an intramuscular (IM) injection
Study NCT00813098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX1031 High Dose
Description: A high dose of LX1031; daily oral intake for 28 days
Study NCT00813098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX1031 Low Dose
Description: A low dose of LX1031; daily oral intake for 28 days.
Study NCT00813098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo dosing with daily oral intake
Study NCT05225207 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: No intervention will be administered.
Study NCT03757078 — intervention group
Intervention type: DRUG
Intervention: Relief Pro cream
Description: Relief Pro cream:1.0 mg/gm Fluocortolone + 20 mg/gm Lidocaine; Administration according to clinical practice.
Study NCT03757078 — intervention group
Intervention type: DRUG
Intervention: Relief Pro rectal suppositories
Description: Relief Pro rectal suppositories: 1.0 mg Fluocortolone + 40 mg Lidocaine; Administration according to clinical practice
Study NCT00578162 — intervention group
Intervention type: BEHAVIORAL
Intervention: we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER
Description: A cancer care facility or 'agency' is the study's unit of analysis. Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory
Study NCT00549978 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cilostazol
Description: cilostazol, then cilostazol/probucol
Study NCT00549978 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Probucol
Description: Probucol probucol/ cilostazol
Study NCT01154062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib tablet
Study NCT02196805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A: imported Probucol ( Lorelco)
Description: Group A: take imported Probucol( Lorelco) (250mg/tablet), Qd, P.O.
Study NCT02196805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B: Marketed Probucol ( Chang Tai)
Description: Group B: take Marketed Probucol(Chang Tai)(250mg/tablet), Qd, P.O.
Study NCT01233999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: botulinum toxin A
Description: Botulinum toxin A will be injected into participants hand total 40units
Study NCT01910883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 200 mg
Study NCT01910883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 400 mg
Study NCT01910883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 600 mg
Study NCT01910883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 800 mg
Study NCT02074800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328 (CHO-derived)
Description: Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
Study NCT01910883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin i.v. solution 1000 mg
Study NCT01910883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo i.v. solution
Study NCT02074800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single-dose of matching placebo intravenously in Part 1.
Study NCT03701685 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: nerve flap
Description: sensory reconstruction via a nerve graft included in the flap
Study NCT02410213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Study NCT03564093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Drug
Description: 1µg/kg of dexmedetomidine is given 30 minutes prior to intravenous cannulation or lumbar puncture
Study NCT03564093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Drug
Description: Intranasal 4,5% saline is given as a placebo 30 minutes prior to intravenous cannulation or lumbar puncture
Study NCT03848624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling Group
Description: Electrical pulses from a stimulator can stimulate the target muscles to generate muscle contraction to support a continuous cycling motion
Study NCT02322333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLD10
Study NCT02322333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01494701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection
Study NCT03213418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Contingency management is an evidence-based psychotherapy program that promotes behavioral change with financial incentives.
Study NCT04170036 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: protein supplement
Description: Protein supplement usage for at least three preceding months in varied amounts
Study NCT01863732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
Study NCT01863732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Pbo)
Description: Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
Study NCT02672163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CABG surgery
Description: Elective CABG surgery
Study NCT02672163 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG surgery
Description: Elective CABG surgery
Study NCT02672163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AADC therapy
Description: Atrial appendage derived cells are placed on the site of a infarct scar with matrix sheet
Study NCT02044419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide
Study NCT01117753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OutPatient Treatment for Adolescents (OPT-A)
Study NCT01117753 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Study NCT03851913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAI
Description: transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
Study NCT02008968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allopurinol 300 mg./day
Study NCT02008968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Study NCT02008968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normouricemic
Study NCT01849796 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.
Study NCT01849796 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.
Study NCT00996580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-103
Description: One tablet daily.~Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE.
Study NCT03655522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAVX-010
Description: Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Four patients per active group. Each subject participated in only 1 treatment period.
Study NCT03655522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There were two Placebos per group.
Study NCT00450515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT04034316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cord-blood mesenchymal stromal cells
Description: The product is packaged in bags suitable for the cryopreservation of cell products. Before administration the cells must be thawed and diluted in an appropriate vol:vol solution: made by saline 78%, human albumin 10%, Acyl-CoA dehydrogenase-A (ACD-A) 12%.
Study NCT00082095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Type=exact number, unit=mg/m2, number=40, form=infusion, route=intravenous. Pegylated liposomal doxorubicin will be administered on Day 1 of each cycle. Cycle will be repeated every 28 days, up to 1 year.
Study NCT00082095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Type=exact number, unit=mg, number=500, form=tablet, route=oral. Capecitabine will be administered at a dosage of 1000 mg/m2 twice daily for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
Study NCT02609373 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep intervention
Description: Session 1: Intervener \& participant review 2-week sleep diary and actigraph data. Provide individualized sleep hygiene prescription.~Session 2: Review sleep diary; calculate sleep efficiency; identify adjustments needed.~Session 3: Review sleep-related vs. stress-related symptoms. Develop plan for sleep-related symptoms and discuss Sleep Restriction with Relaxation Exercises. Session 4: Reinforce progress and make corrections as required. If Sleep Restriction is not working, Stimulus Control is introduced.~Session 5-10: Provide reinforcement, assess adherence, answer questions, and offer encouragement and monitoring, including alterations as required.~Booster sessions: At 8 \& 10 months: reinforcement, question answering, encouragement and monitoring.
Study NCT04006678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer guided sandwich osteotomy
Description: segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
Study NCT04006678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: computer guided sandwich osteotomy
Description: segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
Study NCT02333266 — intervention group
Intervention type: OTHER
Intervention: Candidemia